How You Can Profit From the Next Big Thing in Healthcare

Precision medicine is going to be huge. Two stocks in particular — Illumina and Roche — provide investors a way to profit.

What’s the next big thing coming for healthcare?

Results from the New England Journal of Medicine (NEJM) Catalyst Insights Survey on Care Redesign suggest that genomics and patient-generated data critical for precision medicine could surge in importance over the next five years. Savvy investors could profit from this increased demand for precision medicine data by buying two specific stocks: Illumina (NASDAQ:ILMN) and Roche(NASDAQOTH:RHHBY). Here’s why.

The next generation of next-generation sequencing

Mapping the first human genome cost somewhere between $500 million and $1 billion, according to the National Human Genome Research Institute. Illumina’s HiSeq next-generation sequencing system, first introduced in 2010, brought the cost of mapping a human genome down to $1,000. Now Illumina is launching the next generation in next-generation sequencing systems: NovaSeq.

Illumina CEO Francis deSouza predicts that the NovaSeq architecture will pave the way for a $100 genome. Even before that milestone is achieved, NovaSeq’s lower per-sample consumable costs should allow laboratories that couldn’t afford sequencing technology in the past an option to map human genomes for around $1,000 each — potentially fueling the growth of precision medicine.

Probably no company has impacted the field of genomic sequencing as much as Illumina. First incorporated in 1998, Illumina now claims nearly 10,000 sequencing systems in use across the world — from the lower-throughput and lower-cost MiniSeq to the top-end HiSeq X system. The launch of NovaSeq positions Illumina to continue its dominance in genomic sequencing.

Illumina stock isn’t cheap. Shares currently trade at a whopping 54 times trailing earnings. Investors shouldn’t be too afraid of that high valuation, though. It’s actually on the lower end of the historical earnings multiple range for Illumina. If demand for precision medicine grows as expected, Illumina should be one of the primary beneficiaries.

Covering both key parts of precision medicine

Precision medicine involves diagnostics and development. Diagnostics are needed to determine the genetic profiles of patients. But without development of drugs that target specific genetic variations, precision medicine wouldn’t be possible. Roche covers both.

Roche’s diagnostics business segment markets instruments and tests that allow doctors to quickly determine appropriate treatment decisions. The healthcare giant is also at the forefront of developing precision medicines. Roche’s Herceptin was the first precision medicine on the market, gaining U.S. regulatory approval in 1998.

The company’s Genentech Research and Early Development (gRED) group is leveraging Roche’s expertise in biomarkers (molecules found in blood, other body fluids, or tissues that can point to annormalities or diseases) and diagnostics to identify the best combinations of drugs for treating specific diseases. Roche is using this approach in a significant way with its cancer drug Tecentriq, which is being evaluated as a backbone for multiple combination therapies.

Tecentriq is just one of several drugs that could drive growth for Roche in the coming years. Sales are soaring for another cancer drug, Perjeta, as well as for autoimmune disease drug Actemra and anti-inflammatory Xolair. Roche should also enjoy success with multiple sclerosis drug Ocrevus, which awaits regulatory approval.

There are some major hurdles for the company, however. MabThera/Rituxan already faces biosimilar competition in Europe. Roche’s recent deal with Mylan clears the way for biosimilar rivals for Herceptin in the near future. Avastin loses patent exclusivity in 2020. The three drugs are Roche’s biggest moneymakers right now.

Bigger precision medicine winner?

Both Illumina and Roche should profit from the expansion of precision medicine. Which company will be the bigger winner? I’d go with Illumina.

Illumina is about as pure-play as you can get for precision medicine. Back in the gold rush days, the ones who made the most money weren’t the gold miners but rather the merchants who sold the shovels to the miners. That’s essentially what Illumina does for precision medicine. Its genomic sequencing systems are the shovels that make precision medicine possible.

I don’t think Illumina’s share price will skyrocket nearly 1,000% like it did over the last 10 years. However, if you’re looking to profit from the next big thing in healthcare, Illumina is probably the best pick on the market.

Forget Illumina: “Total conviction” buy signal issued
The Motley Fool’s co-founders, David and Tom Gardner, rarely agree on a stock. But when they do, their picks have beaten the market by 6X on average.*

That’s why many investors consider their joint stamp of approval to be a “total conviction” signal to buy. The Motley Fool recently announced a new “total conviction” stock…and it wasn’t Illumina!

Click here to learn more about the stock.

*Returns as of March 13th, 2017.

Keith Speights has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Illumina. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

You May Also Like

Pride Week Festival Begins With Tribute to Pulse Nightclub Survivor

Miami Beach Pride’s week-long festivities will commence with a special tribute to the LGBTQ+ community honoring the victims of the tragic shooting at Pulse Nightclub in Orlando. A ceremonial “flip

Surfside luxury condo sees notable sales

Arte at Surfside is making waves. There’s, of course, the news that Ivanka Trump and Jared Kushner are renting at the 16-resident luxury condominium. And there’s the December penthouse sale

Up in the Air: A Discussion

In a dynamic region where residents are typically on the move, everyone is wondering about the health of the airline industry and the safety of airports and airplanes. Everyone is

South Florida Yachting Legend Passes

Robert “Bob” Roscioli, an icon in the South Florida marine industry, has passed away. Many recognize the name Roscioli from the widely-successful and world-renowned Roscioli Yachting Center, a full service

Other Posts

Four key steps

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column width=”2/3″][vc_column_text] What a crazy time we are all experiencing. Right now, getting back to basics is most important. It is not and

Pandemic adds to worries about hurricane season

An above-normal 2020 Atlantic hurricane season is expected, according to forecasters with NOAA’s Climate Prediction Center, a division of the National Weather Service. The outlook predicts a 60% chance of

The difference between leading and managing

[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column width=”2/3″][vc_column_text] Leadership and management are often misunderstood as one in the same. They are not. Certainly, a good leader should be able

Flattening the housing curve in a pandemic

By Josh Migdal In the classic film Groundhog Day (and yes, it is a classic), Bill Murray’s character wakes up over and over again in Punxsutawney, Pennsylvania, reliving the same

Drew Limsky

Drew Limsky



Drew Limsky joined Lifestyle Media Group in August 2020 as Editor-in-Chief of South Florida Business & Wealth. His first issue of SFBW, October 2020, heralded a reimagined structure, with new content categories and a slew of fresh visual themes. “As sort of a cross between Forbes and Robb Report, with a dash of GQ and Vogue,” Limsky says, “SFBW reflects South Florida’s increasingly sophisticated and dynamic business and cultural landscape.”

Limsky, an avid traveler, swimmer and film buff who holds a law degree and Ph.D. from New York University, likes to say, “I’m a doctor, but I can’t operate—except on your brand.” He wrote his dissertation on the nonfiction work of Joan Didion. Prior to that, Limsky received his B.A. in English, summa cum laude, from Emory University and earned his M.A. in literature at American University in connection with a Masters Scholar Award fellowship.

Limsky came to SFBW at the apex of a storied career in journalism and publishing that includes six previous lead editorial roles, including for some of the world’s best-known brands. He served as global editor-in-chief of Lexus magazine, founding editor-in-chief of custom lifestyle magazines for Cadillac and Holland America Line, and was the founding editor-in-chief of Modern Luxury Interiors South Florida. He also was the executive editor for B2B magazines for Acura and Honda Financial Services, and he served as travel editor for Conde Nast. Magazines under Limsky’s editorship have garnered more than 75 industry awards.

He has also written for many of the country’s top newspapers and magazines, including The New York Times, Washington Post, Los Angeles Times, Miami Herald, Boston Globe, USA Today, Worth, Robb Report, Afar, Time Out New York, National Geographic Traveler, Men’s Journal, Ritz-Carlton, Elite Traveler, Florida Design, Metropolis and Architectural Digest Mexico. His other clients have included Four Seasons, Acqualina Resort & Residences, Yahoo!, American Airlines, Wynn, Douglas Elliman and Corcoran. As an adjunct assistant professor, Limsky has taught journalism, film and creative writing at the City University of New York, Pace University, American University and other colleges.